University of Limoges
Also known as: Centre Hospitalier Esquirol | Centre Hospitalier Universitaire de Limoges | Centre Hospitalier Universitaire de Limoges CHU Dupuytren 2 Avenue Martin Luther King 87042 Limoges Cedex, France | Centre Hospitalier Universitaire de Limoges, CHUL, France | Centre Hospital Regional Universitaire de Limoges | CH Limoges | CHU 86000 Limoges | CHU de Limoges, medical oncology department ,02 avenue Martin Luther King 87042 Limoges cedex France | CHU Limoges | CHU LImoges | CHU LIMOGES | CHU Limoges - Limoges | Department of Biochemistry and Molecular Genetics, Limoges University, Limoges, France | HOPITAL DUPUYTREN - LIMOGES | HOPITAL DUPUYTREN - LIMOGES CEDEX 1 | Inserm U1111, Lyon | J. Rebeyrol Hospital in Limoges | J. Rebeyrol Hospital, Limoges | Limoges (FR), University College Hospital | Limoges Hospital | Limoges UH | Limoges University | University Hospital, Limoges | University Hospital, Limoges, France
Highest phase reached
Phase 4
First clinical trial
Aug 1, 1999Last known activity
Nov 2, 2025
Timeline
1960s
- Jan 1, 1968
University of Limoges— Founded
Drugs by trial phase (100 distinct, 79 trials)
Phase 4 (18 own, 0 via acquisition)
Phase 3 (38 own, 0 via acquisition)
Phase 2 (35 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (8 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Amyloidosis
- Anemia
- Aortic Valve Stenosis
- Apnea
- Arteritis
- Autistic Disorder
- Calcinosis
- Carcinoma, Non-Small-Cell Lung
- Cardiac Complexes, Premature
- Cardiomyopathies
- Colorectal Neoplasms
- Communicable Diseases
- Constriction, Pathologic
- Dermatomyositis
- Down Syndrome
- Edema
- Fatigue
- Fibromyalgia
- Fibrosis
- Giant Cell Arteritis
- Graft vs Host Disease
- Head and Neck Neoplasms
- Heart Arrest
- Hemiplegia
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Hypertrophy
- Hypertrophy, Left Ventricular
- Hypothermia
- Immune System Diseases
- Immunoglobulin Light-chain Amyloidosis
- Infections
- Intraabdominal Infections
- Ischemia
- Keratosis
- Keratosis, Actinic
- Kidney Diseases
- Kidney Failure, Chronic
- Laryngeal Edema
- Lung Neoplasms
- Lymphocele
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphopenia
- Monoclonal Gammopathy of Undetermined Significance
- Multiple Myeloma
- Muscle Spasticity
- Myofascial Pain Syndromes
- Neoplasms, Plasma Cell
- Nephrosis
- Nephrosis, Lipoid
- Nephrotic Syndrome
- Neuralgia
- Paraproteinemias
- Pemphigoid, Benign Mucous Membrane
- Pemphigoid, Bullous
- Pemphigus
- Peripheral Nervous System Diseases
- Pneumococcal Infections
- Pneumonia
- Pneumonia, Bacterial
- Pneumonia, Ventilator-Associated
- POEMS Syndrome
- Polymyalgia Rheumatica
- Polyneuropathies
- Prostatic Neoplasms
- Prosthesis Failure
- Psoriasis
- Recurrence
- Respiratory Insufficiency
- Retinal Neoplasms
- Retinoblastoma
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Sepsis
- Shock
- Shock, Cardiogenic
- Sleep Apnea Syndromes
- Syndrome
- Thrombosis
- Toxemia
- Urticaria
- Ventricular Dysfunction, Left
Recent trials (50)
- NCT07019818Lead sponsorPhase 4Nov 2, 2025
- NCT06892951CollaboratorPhase 1/Phase 2Jun 30, 2025
- NCT06649695OfficialPhase 2Mar 31, 2025
- NCT06354179Lead sponsorPhase 4Jul 1, 2024
- NCT06026228CollaboratorN/AJan 31, 2024
- NCT06150469Lead sponsorN/ADec 16, 2023
- NCT05795647Lead sponsorPhase 2Nov 20, 2023
- NCT05795647Overall official - principal investigatorPhase 2Nov 20, 2023
- NCT05066607Overall official - principal investigatorPhase 2Dec 31, 2021
- NCT04526353Overall official - principal investigatorPhase 2Sep 10, 2020
- NCT04407689Study chairPhase 2Jun 1, 2020
- NCT04407689CollaboratorPhase 2Jun 1, 2020
- NCT04350086Lead sponsorPhase 4Apr 20, 2020
- NCT04166331Lead sponsorPhase 3Feb 1, 2020
- NCT04166331Overall official - principal investigatorPhase 3Feb 1, 2020
Details
- Founded
- Limoges, FR Jan 1, 1968
- Last known activity
- Nov 2, 2025